Sandip Patel

Title(s)Professor Of Clinical, Medicine
SchoolVc-health Sciences-schools
vCardDownload vCard

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473590. Azenkot T, Rivera DR, Stewart MD, Patel SP. PMID: 40403202.
      View in: PubMed   Mentions:    Fields:    
    2. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. Cancer Commun (Lond). 2025 May 22. Chae YK, Othus M, Patel SP, Aljumaily R, Win KZ, Pejovic T, Thomas SS, Robinson WR, Kim HS, Chung LI, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. PMID: 40402690.
      View in: PubMed   Mentions:    Fields:    
    3. Real-World Analysis of Disparities in Biomarker Testing and Use of Recommended Targeted Therapies in Metastatic Non-Small Cell Lung Cancer in the United States. JCO Precis Oncol. 2025 May; 9:e2400449. Dennis MJ, Abrahami D, Vieira MC, Benjumea D, Boyd M, Shao A, Kelton J, Patel SP. PMID: 40373260.
      View in: PubMed   Mentions:    Fields:    
    4. Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Apr 01; 31(7):1233-1242. Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP. PMID: 39846804; PMCID: PMC11964177.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    5. Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma. NPJ Precis Oncol. 2025 Jan 24; 9(1):24. Patel SP, Cano-Linson E, Chae YK, Schokrpur S, Lao CD, Powers BC, Victor AI, Onitilo AA, Shin S, Takebe N, Threlkel S, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke CD, Kurzrock R. PMID: 39856213; PMCID: PMC11759674.
      View in: PubMed   Mentions:
    6. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):308-315. Chae YK, Corthell L, Patel SP, Edwards R, Scalici JM, Kim HS, Chung LI, Othus M, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. PMID: 39561273; PMCID: PMC11804806.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    7. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16; 30(24):5593-5600. Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, Schallenkamp JM, Adra N, Appleman LJ, Alden M, Thomes Pepin J, Ellerton JA, Poklepovic A, Walter A, Rampurwala MM, Robinson WR, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. PMID: 39417692; PMCID: PMC11737520.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    8. Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma). Ther Adv Med Oncol. 2024; 16:17588359241293401. Chae YK, Othus M, Patel SP, Gerber DE, Tanvetyanon T, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. PMID: 39583952; PMCID: PMC11583498.
      View in: PubMed   Mentions:
    9. Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade. medRxiv. 2024 Aug 08. Mathews IT, Saminathan P, Henglin M, Liu M, Nadig N, Fang C, Mercader K, Chee SJ, Campbell AM, Patel AA, Tiwari S, Watrous JD, Ramesh K, Dicker M, Dao K, Meyer MA, Jousilahti P, Havulinna AS, Niiranen T, Salomaa V, Joosten LAB, Netea MG, Zheng P, Kronenberg M, Patel SP, Gutkind JS, Ottensmeier C, Long T, Kaech SM, Hedrick CC, Cheng S, Jain M, Sharma S. PMID: 39148854; PMCID: PMC11326322.
      View in: PubMed   Mentions:
    10. Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort. J Immunother Cancer. 2024 Jul 27; 12(7). Patel SP, Othus M, Chae YK, Huynh T, Tan B, Kuzel T, McLeod C, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke C, Kurzrock R. PMID: 39067873; PMCID: PMC11284838.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    11. PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections. Sci Transl Med. 2024 07 03; 16(754):eadi6887. Shepard RM, Ghebremedhin A, Pratumchai I, Robinson SR, Betts C, Hu J, Sasik R, Fisch KM, Zak J, Chen H, Paradise M, Rivera J, Amjad M, Uchiyama S, Seo H, Campos AD, Dayao DA, Tzipori S, Piedra-Mora C, Das S, Hasteh F, Russo H, Sun X, Xu L, Crotty Alexander LE, Duran JM, Odish M, Pretorius V, Kirchberger NC, Chin SM, Von Schalscha T, Cheresh D, Morrey JD, Alargova R, O'Connell B, Martinot TA, Patel SP, Nizet V, Martinot AJ, Coussens LM, Teijaro JR, Varner JA. PMID: 38959328; PMCID: PMC11272418.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    12. Retraction Note: Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2024 Jul; 631(8021):694. Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ, Kanbar J, Miller-Montgomery S, Heaton R, Mckay R, Patel SP, Swafford AD, Knight R. PMID: 38926587.
      View in: PubMed   Mentions: 3     Fields:    
    13. Integrating clinical research into electronic health record workflows to support a learning health system. JAMIA Open. 2024 Jul; 7(2):ooae023. Goldhaber NH, Jacobs MB, Laurent LC, Knight R, Zhu W, Pham D, Tran A, Patel SP, Hogarth M, Longhurst CA. PMID: 38751411; PMCID: PMC11095974.
      View in: PubMed   Mentions: 2  
    14. Correction: Robustness of cancer microbiome signals over a broad range of methodological variation. Oncogene. 2024 May; 43(20):1579. Sepich-Poore GD, McDonald D, Kopylova E, Guccione C, Zhu Q, Austin G, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf JL, Song SJ, Kanbar J, Miller-Montgomery S, Heaton R, Mckay R, Patel SP, Swafford AD, Korem T, Knight R. PMID: 38580705; PMCID: PMC11090788.
      View in: PubMed   Mentions:    Fields:    
    15. Validation of an Updated Algorithm to Identify Patients With Incident Non-Small Cell Lung Cancer in Administrative Claims Databases. JCO Clin Cancer Inform. 2024 03; 8:e2300165. Patel SP, Wang R, Zhou SQ, Sheinson D, Johnson A, Lee JS. PMID: 38502111; PMCID: PMC10965218.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    16. Robustness of cancer microbiome signals over a broad range of methodological variation. Oncogene. 2024 Apr; 43(15):1127-1148. Sepich-Poore GD, McDonald D, Kopylova E, Guccione C, Zhu Q, Austin G, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf JL, Song SJ, Kanbar J, Miller-Montgomery S, Heaton R, Mckay R, Patel SP, Swafford AD, Korem T, Knight R. PMID: 38396294; PMCID: PMC10997506.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    17. SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer. Cancer. 2024 Sep 01; 130(17):2918-2927. Patel SP, Guadarrama E, Chae YK, Dennis MJ, Powers BC, Liao CY, Ferri WA, George TJ, Sharon E, Ryan CW, Othus M, Lopez G, Blanke CD, Kurzrock R. PMID: 38358334; PMCID: PMC11309904.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    18. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors. J Immunother Cancer. 2024 Feb 02; 12(2). Patel SP, Alonso-Gordoa T, Banerjee S, Wang D, Naidoo J, Standifer NE, Palmer DC, Cheng LY, Kourtesis P, Ascierto ML, Das M, Diamond JR, Hellmann MD, Carneiro BA. PMID: 38309722; PMCID: PMC10840023.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    19. Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy. Front Immunol. 2024; 15:1322187. Dennis MJ, Bylsma S, Madlensky L, Pagadala MS, Carter H, Patel SP. PMID: 38348036; PMCID: PMC10859432.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    20. Immuno-Oncology: New Insights into Targets and Therapies. Surg Oncol Clin N Am. 2024 Apr; 33(2):265-278. Schokrpur S, White MG, Roland CL, Patel SP. PMID: 38401909.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    21. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia. Clin Cancer Res. 2024 01 05; 30(1):33-38. Patel SP, Othus M, Chae YK, Dennis MJ, Gordon S, Mutch D, Samlowski W, Robinson WRR, Sharon E, Ryan C, Lopez G, Plets M, Blanke C, Kurzrock R. PMID: 37882676; PMCID: PMC10842092.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    22. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer. 2023 Jul 28; 23(1):708. Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, Zhao Y, Gueorguieva I, Man M, Estrem ST, Liu J, Avsar E, Lin WH, Benhadji KA, Gandhi L, Guba SC, Diaz IA. PMID: 37507657; PMCID: PMC10386782.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    23. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 07 07; 13(7):1556-1571. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. PMID: 37068173; PMCID: PMC11024958.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    24. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response. Nat Commun. 2023 05 12; 14(1):2744. Pagadala M, Sears TJ, Wu VH, Pérez-Guijarro E, Kim H, Castro A, Talwar JV, Gonzalez-Colin C, Cao S, Schmiedel BJ, Goudarzi S, Kirani D, Au J, Zhang T, Landi T, Salem RM, Morris GP, Harismendy O, Patel SP, Alexandrov LB, Mesirov JP, Zanetti M, Day CP, Fan CC, Thompson WK, Merlino G, Gutkind JS, Vijayanand P, Carter H. PMID: 37173324; PMCID: PMC10182072.
      View in: PubMed   Mentions: 18     Fields:    Translation:Cells
    25. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023 Jul; 72(7):2443-2458. Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. PMID: 37016126; PMCID: PMC10264501.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    26. CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. J Thorac Oncol. 2023 05; 18(5):650-656. Kim DW, Kim SW, Camidge DR, Shu CA, Marrone KA, Le X, Blakely CM, Park K, Chang GC, Patel SP, Kar G, Cooper ZA, Samadani R, Pluta M, Kumar R, Ramalingam S. PMID: 36641093.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    27. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell. 2022 09 29; 185(20):3789-3806.e17. Narunsky-Haziza L, Sepich-Poore GD, Livyatan I, Asraf O, Martino C, Nejman D, Gavert N, Stajich JE, Amit G, González A, Wandro S, Perry G, Ariel R, Meltser A, Shaffer JP, Zhu Q, Balint-Lahat N, Barshack I, Dadiani M, Gal-Yam EN, Patel SP, Bashan A, Swafford AD, Pilpel Y, Knight R, Straussman R. PMID: 36179670; PMCID: PMC9567272.
      View in: PubMed   Mentions: 177     Fields:    Translation:HumansAnimals
    28. Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer. Oncologist. 2022 09 02; 27(9):e739-e747. Chen R, Hakimi K, Zhang X, Messer K, Patel SP. PMID: 35816018; PMCID: PMC9438912.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    29. Resistance to EGFR Tyrosine Kinase Inhibitor Therapy in Non-Small-Cell Lung Cancer via Newly Acquired Targetable Oncogenic Driver Alterations With an Emphasis on BRAF: Case Series and Literature Review of Treatment. JCO Precis Oncol. 2022 08; 6:e2100551. Giustini NP, Patel SP, Myall NJ, Fernando do Prado Moura J, Kulkarni A, Chao RC, Wakelee H, Bazhenova L. PMID: 35952324.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    30. CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer. Front Immunol. 2022; 13:842653. Olingy C, Alimadadi A, Araujo DJ, Barry D, Gutierrez NA, Werbin MH, Arriola E, Patel SP, Ottensmeier CH, Dinh HQ, Hedrick CC. PMID: 35493454; PMCID: PMC9046782.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    31. Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy. Transl Lung Cancer Res. 2022 Mar; 11(3):452-461. Yu L, Bazhenova L, Gold K, Tran L, Hilburn V, Vu P, Patel SP. PMID: 35399568; PMCID: PMC8988081.
      View in: PubMed   Mentions: 9  
    32. Disparities in telemedicine during COVID-19. Cancer Med. 2022 02; 11(4):1192-1201. Qian AS, Schiaffino MK, Nalawade V, Aziz L, Pacheco FV, Nguyen B, Vu P, Patel SP, Martinez ME, Murphy JD. PMID: 34989148; PMCID: PMC8855911.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansCells
    33. Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials. Cancer. 2022 02 15; 128(4):770-777. Javier-DesLoges J, Nelson TJ, Murphy JD, McKay RR, Pan E, Parsons JK, Kane CJ, Kader AK, Derweesh IH, Nodora J, Patel SP, Martinez ME, Rose BS. PMID: 34806168.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    34. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 01 15; 28(2):271-278. Adams S, Othus M, Patel SP, Miller KD, Chugh R, Schuetze SM, Chamberlin MD, Haley BJ, Storniolo AMV, Reddy MP, Anderson SA, Zimmerman CT, O'Dea AP, Mirshahidi HR, Ahnert JR, Brescia FJ, Hahn O, Raymond JM, Biggs DD, Connolly RM, Sharon E, Korde LA, Gray RJ, Mayerson E, Plets M, Blanke CD, Chae YK, Kurzrock R. PMID: 34716198; PMCID: PMC8776596.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCTClinical Trials
    35. Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 01 01; 28(1):95-105. Rottey S, Clarke J, Aung K, Machiels JP, Markman B, Heinhuis KM, Millward M, Lolkema M, Patel SP, de Souza P, Duca M, Curigliano G, Santoro A, Koyama T, Brown M, Vezina H, He C, Chu QS. PMID: 34615718; PMCID: PMC9401510.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    36. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep. 2021 08 30; 11(1):17324. Makunts T, Saunders IM, Cohen IV, Li M, Moumedjian T, Issa MA, Burkhart K, Lee P, Patel SP, Abagyan R. PMID: 34462476; PMCID: PMC8405813.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    37. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021 09 01; 127(17):3194-3201. Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R. PMID: 33882143; PMCID: PMC8606104.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    38. IMpower 132: Loses Power at the Finish Line. J Thorac Oncol. 2021 04; 16(4):512-514. Patel SP, Kelly K. PMID: 33781439.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Commentary: Induction Immunotherapy: Intriguing Initiative for Investigation. Semin Thorac Cardiovasc Surg. 2021; 33(3):858-859. Patel SP, Onaitis M. PMID: 33662553.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Author Correction: Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions. Sci Rep. 2020 Nov 20; 10(1):20641. Gago-Dominguez M, Matabuena M, Redondo CM, Patel SP, Carracedo A, Ponte SM, Martínez ME, Castelao JE. PMID: 33219311; PMCID: PMC7680152.
      View in: PubMed   Mentions: 1     Fields:    
    41. Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol. 2021 01; 15(1):67-79. Charo LM, Eskander RN, Okamura R, Patel SP, Nikanjam M, Lanman RB, Piccioni DE, Kato S, McHale MT, Kurzrock R. PMID: 32881280; PMCID: PMC7782073.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    42. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 10 15; 26(20):5358-5367. Glisson BS, Leidner RS, Ferris RL, Powderly J, Rizvi NA, Keam B, Schneider R, Goel S, Ohr JP, Burton J, Zheng Y, Eck S, Gribbin M, Streicher K, Townsley DM, Patel SP. PMID: 32816951.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansCTClinical Trials
    43. Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions. Sci Rep. 2020 08 06; 10(1):13203. Gago-Dominguez M, Matabuena M, Redondo CM, Patel SP, Carracedo A, Ponte SM, Martínez ME, Castelao JE. PMID: 32764699; PMCID: PMC7413522.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    44. ALKBH5 regulates anti-PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020 08 18; 117(33):20159-20170. Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, Agrawal K, Gonzalez GM, Wang Y, Patel SP, Rana TM. PMID: 32747553; PMCID: PMC7443867.
      View in: PubMed   Mentions: 298     Fields:    Translation:HumansCells
    45. Rapid onset type 1 diabetes with anti-PD-1 directed therapy. Oncotarget. 2020 Jul 14; 11(28):2740-2746. Yun K, Daniels G, Gold K, Mccowen K, Patel SP. PMID: 32733645; PMCID: PMC7367652.
      View in: PubMed   Mentions: 9     Fields:    
    46. Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clin Cancer Res. 2020 05 15; 26(10):2434. Patel SP, Othus M, Chae YK, Kurzrock R, S1609 Team. PMID: 32414761.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020 03; 579(7800):567-574. Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ, Kanbar J, Miller-Montgomery S, Heaton R, Mckay R, Patel SP, Swafford AD, Knight R. PMID: 32214244; PMCID: PMC7500457.
      View in: PubMed   Mentions: 494     Fields:    Translation:Humans
    48. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 09; 21(5):e435-e444. Naidoo J, Nishino M, Patel SP, Shankar B, Rekhtman N, Illei P, Camus P. PMID: 32576443.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    49. Phase Ib Study of Crizotinib plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation. Oncologist. 2020 07; 25(7):562-e1012. Patel SP, Pakkala S, Pennell NA, Reckamp KL, Lanzalone S, Polli A, Tarazi J, Robert-Vizcarrondo F. PMID: 32048771; PMCID: PMC7356710.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    50. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020 05 15; 26(10):2290-2296. Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. PMID: 31969335; PMCID: PMC7231627.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansCTClinical Trials
    51. Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patients. Transl Cancer Res. 2020 Jan; 9(1):203-209. Porter A, Natsuhara M, Daniels GA, Patel SP, Sacco AG, Bykowski J, Banks KC, Cohen EEW. PMID: 35117174; PMCID: PMC8798156.
      View in: PubMed   Mentions: 13  
    52. Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade. Oncology. 2020; 98(2):123-130. Galant-Swafford J, Troesch A, Tran L, Weaver A, Doherty TA, Patel SP. PMID: 31665718; PMCID: PMC7292032.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    53. Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale. Mayo Clin Proc Innov Qual Outcomes. 2019 Jun; 3(2):235-237. Tyan A, Patel SP, Block S, Hughes T, McCowen KC. PMID: 31193884; PMCID: PMC6543257.
      View in: PubMed   Mentions: 9  
    54. GABABR-Mediated Paraneoplastic Limbic Encephalitis Due To Thymic Small Cell Carcinoma. J Gen Intern Med. 2019 08; 34(8):1658-1661. Bordin-Wosk T, Patel SP, Horman SF. PMID: 31062226; PMCID: PMC6667585.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. PMID: 31058253; PMCID: PMC6497417.
      View in: PubMed   Mentions: 39     Fields:    
    56. Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast. 2019 Apr; 44:29-32. Tray N, Taff J, Singh B, Suh J, Ngo N, Kwa M, Troxel AB, Chae YK, Kurzrock R, Patel SP, Sharon E, Denkert C, Ross JS, Adams S. PMID: 30609392.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    57. Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series. JCO Precis Oncol. 2018 Nov; 2:1-10. Jacobs MT, Mohindra NA, Shantzer L, Chen IL, Phull H, Mitchell W, Raymond VM, Banks KC, Nagy RJ, Lanman RB, Christensen J, Patel JD, Clarke J, Patel SP. PMID: 35135131.
      View in: PubMed   Mentions: 7     Fields:    
    58. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 09 25; 6(1):93. Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P. PMID: 30253804; PMCID: PMC6156919.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCellsCTClinical Trials
    59. Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment. Oncologist. 2018 10; 23(10):1236-1241. Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP. PMID: 29769383; PMCID: PMC6263128.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    60. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. Clin Cancer Res. 2017 Oct 01; 23(19):5729-5736. Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R. PMID: 28972084; PMCID: PMC5678984.
      View in: PubMed   Mentions: 122     Fields:    Translation:Humans
    61. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. PMID: 28835386; PMCID: PMC5670009.
      View in: PubMed   Mentions: 1219     Fields:    Translation:HumansAnimalsCells
    62. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models. Clin Cancer Res. 2017 Nov 01; 23(21):6661-6672. Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG. PMID: 28765324.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    63. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. PMID: 28550027; PMCID: PMC5469598.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    64. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. PMID: 28539465; PMCID: PMC5581668.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    65. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017 03; 36(1):179-190. Khagi Y, Kurzrock R, Patel SP. PMID: 27873079; PMCID: PMC5385298.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimals
    66. Impact of Integrating Rumke Statistics to Assist with Choosing Between Automated Hematology Analyzer Differentials vs Manual Differentials. J Appl Lab Med. 2017 Jan 01; 1(4):357-364. Stephens L, Hintz-Prunty W, Bengtsson HI, Proudfoot JA, Patel SP, Broome HE. PMID: 33636799.
      View in: PubMed   Mentions: 2     Fields:    
    67. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 04; 14(4):203-220. Goodman A, Patel SP, Kurzrock R. PMID: 27805626.
      View in: PubMed   Mentions: 240     Fields:    Translation:Humans
    68. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel SP, Kurzrock R. PMID: 27942391; PMCID: PMC5142752.
      View in: PubMed   Mentions: 60  
    69. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. PMID: 27185373.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    70. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. PMID: 26418953; PMCID: PMC4741715.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015 Apr; 14(4):847-56. Patel SP, Kurzrock R. PMID: 25695955.
      View in: PubMed   Mentions: 1204     Fields:    Translation:HumansAnimals
    72. Designing effective vaccines for colorectal cancer. Immunotherapy. 2014; 6(8):913-26. Patel SP, Osada T, Lyerly HK, Morse MA. PMID: 25313570.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. Cancer Immunol Immunother. 2013 Jun; 62(6):1011-9. Patel SP, Bristol A, Saric O, Wang XP, Dubeykovskiy A, Arlen PM, Morse MA. PMID: 23591984; PMCID: PMC11029159.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    Sandip's Networks
    Concepts (224)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (72)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-14-gb083b170 on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California